Tavio Capital LLC lessened its holdings in Humana Inc (NYSE:HUM) by 18.7% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 53,232 shares of the insurance provider’s stock after selling 12,265 shares during the period. Humana makes up 5.4% of Tavio Capital LLC’s portfolio, making the stock its 8th biggest position. Tavio Capital LLC’s holdings in Humana were worth $15,843,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of the stock. FDx Advisors Inc. increased its holdings in shares of Humana by 42.7% during the first quarter. FDx Advisors Inc. now owns 2,248 shares of the insurance provider’s stock worth $604,000 after buying an additional 673 shares in the last quarter. Commerzbank Aktiengesellschaft FI grew its stake in shares of Humana by 338.9% during the first quarter. Commerzbank Aktiengesellschaft FI now owns 7,913 shares of the insurance provider’s stock valued at $2,127,000 after purchasing an additional 6,110 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Humana by 3.0% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 40,052 shares of the insurance provider’s stock valued at $10,767,000 after purchasing an additional 1,148 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of Humana by 455.5% during the first quarter. Victory Capital Management Inc. now owns 13,737 shares of the insurance provider’s stock valued at $3,693,000 after purchasing an additional 11,264 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in shares of Humana by 80.1% during the first quarter. Massachusetts Financial Services Co. MA now owns 741,942 shares of the insurance provider’s stock valued at $199,454,000 after purchasing an additional 329,956 shares during the last quarter. 93.00% of the stock is owned by hedge funds and other institutional investors.
Several analysts have recently commented on HUM shares. Credit Suisse Group increased their price target on shares of Humana from $350.00 to $370.00 and gave the company an “outperform” rating in a research note on Tuesday. Piper Jaffray Companies reissued a “buy” rating and set a $355.00 price target on shares of Humana in a research note on Thursday, August 2nd. Morgan Stanley started coverage on shares of Humana in a research note on Thursday, July 12th. They set an “overweight” rating and a $362.00 price target on the stock. SunTrust Banks reissued a “hold” rating and set a $350.00 price target on shares of Humana in a research note on Thursday, August 2nd. Finally, Citigroup reissued a “buy” rating and set a $340.00 price target (up from $280.00) on shares of Humana in a research note on Friday, June 1st. Six equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $328.94.
In other news, insider Elizabeth D. Bierbower sold 6,036 shares of Humana stock in a transaction on Monday, June 11th. The shares were sold at an average price of $300.91, for a total transaction of $1,816,292.76. Following the transaction, the insider now directly owns 21,683 shares of the company’s stock, valued at $6,524,631.53. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Elizabeth D. Bierbower sold 3,092 shares of Humana stock in a transaction on Thursday, August 16th. The stock was sold at an average price of $330.00, for a total transaction of $1,020,360.00. Following the transaction, the insider now directly owns 14,289 shares in the company, valued at $4,715,370. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 92,431 shares of company stock worth $28,602,805. Insiders own 0.60% of the company’s stock.
HUM stock traded down $0.68 during midday trading on Thursday, reaching $332.20. The company’s stock had a trading volume of 166 shares, compared to its average volume of 366,950. Humana Inc has a 52 week low of $231.90 and a 52 week high of $336.48. The stock has a market cap of $45.91 billion, a PE ratio of 28.31, a PEG ratio of 1.66 and a beta of 0.96. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.43.
Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, August 1st. The insurance provider reported $3.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.17. Humana had a net margin of 2.48% and a return on equity of 17.43%. The firm had revenue of $14.26 billion for the quarter, compared to analysts’ expectations of $14.16 billion. During the same period last year, the firm earned $3.49 earnings per share. sell-side analysts predict that Humana Inc will post 14.18 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 26th. Shareholders of record on Friday, September 28th will be paid a $0.50 dividend. The ex-dividend date is Thursday, September 27th. This represents a $2.00 dividend on an annualized basis and a yield of 0.60%. Humana’s payout ratio is presently 17.08%.
Humana Inc is a health and well-being company focused on making it easy for people to achieve best health. Its strategy integrates care delivery, the member experience, and clinical & consumer insights to encourage engagement, behavior change, proactive clinical outreach, and wellness for the people.
Featured Story: Diversification For Individual Investors
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.